---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-122777"
form_type: "8-K"
ticker: "OFIX"
cik: "0000884624"
company_name: "Orthofix Medical Inc."
filed_at: "2024-11-07T23:59:59+00:00"
generated_at: "2026-05-30T04:10:31.170153+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Orthofix Q3 net sales $196.6M (+7%), adjusted EBITDA $19.2M, introduces 2027 targets

## Summary
- Net sales $196.6M, +7% YoY; U.S. Spine Fixation +18%, U.S. Orthopedics record quarter +15%.
- Net loss $(27.4)M vs $(28.9)M prior year; adjusted EBITDA $19.2M, margin 9.8% vs 7.3%.
- Free cash flow positive $5.9M in Q3; new $275M credit facility announced.
- Reiterates FY2024 guidance: net sales $795-800M, adjusted EBITDA $64-69M.
- Introduces 2027 targets: 6-7% revenue CAGR, mid-teens adjusted EBITDA margin, positive FCF.

## SEC filing metadata
- accession: 0000950170-24-122777
- form_type: 8-K
- ticker: OFIX
- cik: 0000884624
- company_name: Orthofix Medical Inc.
- filed_at: 2024-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/884624/000095017024122777/0000950170-24-122777-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/884624/000095017024122777/ofix-20241107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-122777
- JSON: https://secwatch.observer/filing/0000950170-24-122777.json
- Plain text: https://secwatch.observer/filing/0000950170-24-122777.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.